Innate Immune Memory in Hematopoietic Stem/Progenitor Cells: Myeloid-Biased Differentiation and the Role of Interferon

Innate immune memory was first described for monocytes and other myeloid cells. This memory is designated Immune Training , in which the host animals that had experienced pathogen infection earlier acquire improved resistance to a second infection. Innate immune memory is mediated by an epigenetic m...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 621333
Main Authors Chen, Lili, Ozato, Keiko
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 29.03.2021
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2021.621333

Cover

More Information
Summary:Innate immune memory was first described for monocytes and other myeloid cells. This memory is designated Immune Training , in which the host animals that had experienced pathogen infection earlier acquire improved resistance to a second infection. Innate immune memory is mediated by an epigenetic mechanism traced to transcriptional memory that is conserved throughout evolution and has been selected for the ability to mount an adaptive response to shifting environments. Accumulating evidence shows that not only peripheral myeloid cells but hematopoietic stem/progenitor cells (HSCs/HSPCs) can acquire epigenetic memory upon pathogen exposure. Systemic pathogen infection causes HSCs to exit from quiescence and facilitate myeloid-biased differentiation that leads to efficient host defense. This sequence of events is common in HSC memory generation, which is triggered by different stimuli. Recent studies show that not only pathogens but other stimuli such as metabolic stress can generate memory in HSCs. This review summarizes recent publications relevant to HSC memory. We discuss the current understanding of initial sensors, soluble mediators/cytokines involved in memory formation, including Type I and Type II interferons along with future implications.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Present address: Lili Chen, Center for Stem Cell and Regenerative Disease, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), The University of Texas Health Science Center at Houston, Houston, TX, United States
Edited by: Jose Luis Subiza, Inmunotek SL, Spain
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
Reviewed by: Hitoshi Takizawa, Kumamoto University, Japan; Maziar Divangahi, McGill University, Canada
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.621333